The stock of Puma Biotechnology Inc (NYSE:PBYI) is a huge mover today! About 177,753 shares traded hands. Puma Biotechnology Inc (NYSE:PBYI) has risen 24.58% since March 15, 2016 and is uptrending. It has outperformed by 19.10% the S&P500.
The move comes after 9 months positive chart setup for the $1.65B company. It was reported on Oct, 18 by Barchart.com. We have $81.47 PT which if reached, will make NYSE:PBYI worth $891.00M more.
Analysts await Puma Biotechnology Inc (NYSE:PBYI) to report earnings on November, 14. They expect $-2.05 earnings per share, down 9.63% or $0.18 from last year’s $-1.87 per share. After $-2.05 actual earnings per share reported by Puma Biotechnology Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Puma Biotechnology Inc (NYSE:PBYI) Ratings Coverage
Out of 6 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Puma Biotechnology Inc has been the topic of 13 analyst reports since August 27, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Thursday, September 22 by Credit Suisse. The rating was initiated by JP Morgan with “Overweight” on Thursday, August 27. The company was initiated on Thursday, January 21 by Credit Suisse. The rating was upgraded by Stifel Nicolaus to “Buy” on Wednesday, September 21. As per Tuesday, March 29, the company rating was downgraded by RBC Capital Markets. The stock of Puma Biotechnology Inc (NYSE:PBYI) has “Outperform” rating given on Tuesday, March 29 by Credit Suisse. The firm has “Buy” rating by Citigroup given on Tuesday, March 29. JP Morgan maintained Puma Biotechnology Inc (NYSE:PBYI) on Tuesday, March 29 with “Overweight” rating. On Monday, December 14 the stock rating was upgraded by Citigroup to “Buy”. The company was maintained on Monday, April 11 by UBS.
According to Zacks Investment Research, “Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.”
Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.18, from 1.03 in 2016Q1. The ratio improved, as 24 funds sold all Puma Biotechnology Inc shares owned while 24 reduced positions. 18 funds bought stakes while 40 increased positions. They now own 31.26 million shares or 4.53% more from 29.91 million shares in 2016Q1.
Cordasco Network, a Pennsylvania-based fund reported 1,000 shares. Point72 Asset Management Lp last reported 1.42 million shares in the company. Janus Cap Mngmt Lc has 0.06% invested in the company for 2.54 million shares. State Board Of Administration Of Florida Retirement Systems has invested 0% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI). Blackrock Limited Liability Company has 91,504 shares for 0% of their US portfolio. Quantitative Ltd has invested 0.02% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI). Rhumbline Advisers, a Massachusetts-based fund reported 27,358 shares. Goldman Sachs Group holds 0% or 133,722 shares in its portfolio. National Bank Of New York Mellon Corporation reported 111,918 shares or 0% of all its holdings. Eaton Vance Mngmt has invested 0.01% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI). Fmr Llc holds 4.87 million shares or 0.02% of its portfolio. Guggenheim Capital Ltd Liability Corporation holds 11,555 shares or 0% of its portfolio. Legal & General Gp Public Limited Co holds 0% or 6,142 shares in its portfolio. Royal Bancorp Of Canada has 925 shares for 0% of their US portfolio. Quantbot Technology L P has 0.02% invested in the company for 6,167 shares.
More notable recent Puma Biotechnology Inc (NYSE:PBYI) news were published by: Fool.com which released: “Why Puma Biotechnology Inc Roared Higher Today” on September 20, 2016, also Prnewswire.com with their article: “Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company …” published on October 11, 2016, Businesswire.com published: “PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick …” on October 15, 2016. More interesting news about Puma Biotechnology Inc (NYSE:PBYI) were released by: Finance.Yahoo.com and their article: “Lawsuit for Investors in shares of Puma Biotechnology Inc (NYSE:PBYI) against …” published on October 04, 2016 as well as Prnewswire.com‘s news article titled: “Johnson & Weaver, LLP Initiates Investigations of Puma Biotechnology, Inc …” with publication date: October 10, 2016.
PBYI Company Profile
Puma Biotechnology, Inc., incorporated on September 15, 2010, is a biopharmaceutical firm that focuses on the development and commercialization of products for the treatment of cancer. The Firm focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2, or HER2, positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.